Tamoxifen Pharmacogenetics in Asian Breast Cancer Women
Information source: Inje University
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Poisoning by, Adverse Effect of and Underdosing of Tamoxifen
Phase: N/A
Status: Recruiting
Sponsored by: Inje University Official(s) and/or principal investigator(s):
JaeGook Shin, MD,PhD, Principal Investigator, Affiliation: Inje University
Overall contact:
Ji-Yeob Choi, Ph.D., Phone: 82-51-890-8663, Email: jychoi@inje.ac.kr
Summary
The clinical outcome of tamoxifen treatment in breast cancer patients may be influenced by
the activity of cytochrome P450 enzymes involving in tamoxifen biotransformation.
Clinical Details
Official title: Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients
Study design: Observational Model: Case-Only, Time Perspective: Retrospective
Primary outcome: Association between genetic polymorphisms of CYP2D6, CYP2C19, and CYP3A5 and disease free survival among tamoxifen treated breast cancer patients
Detailed description:
The investigators investigated the prognostic and/or predictive value of genetic
polymorphisms of enzymes involved in tamoxifen metabolism for the treatment outcome among
Asian breast cancer patients.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- incident breast cancer patients who underwent surgery
Exclusion Criteria:
- previous cancer history before breast cancer diagnosis
Locations and Contacts
Ji-Yeob Choi, Ph.D., Phone: 82-51-890-8663, Email: jychoi@inje.ac.kr
Inje University, Busan 614-735, Korea, Republic of; Recruiting
Ji-Yeob Choi, Ph.D., Phone: 82-51-890-8663, Email: jychoi@inje.ac.kr
Jae-Gook Shin, MD,PhD, Principal Investigator
Additional Information
Starting date: August 2010
Last updated: September 20, 2012
|
